Find your top companies
 High revenue growth  High profit growth
 High EPS growth  High return to investors
 Top 5 in its industry  Best company to work for
 Big employer  Small employer



Video
  • NEXT
    Wal-Mart by the numbers
    A look inside the retail giant, the No. 1 company on the Fortune 500 list - from salaries to its biggest-selling product. Watch
  • NEXT
    BACK
    Customize a Dreamliner
    Boeing, No. 27 on the Fortune 500, relies on thousands of workers around the globe to manufacture each unique 787. Watch
  • NEXT
    BACK
    Nike's run-up to the Olympics
    A major footwear supplier to the Games, and no. 153 on this year's list, says it's not their job to address concerns over human rights in China. Watch
  • BACK
    Apparel giant's success secret
    VF, no. 335 on this year's list, boosts growth by buying successful cult brands, like shoemaker Vans, and giving them freedom to flourish. Watch
FAQ and methodology
Included in the survey are U.S. incorporated companies filing financial statements with a government agency. This includes private companies... More
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe

Our annual ranking of America's largest corporations

  • All
    companies
  • All
    industries
47 of 1000
BACKNEXT
47. Pfizer
Pfizer
Financials: Latest Results
Rank: 47 (Previous rank: 39)
Compare tool: Pfizer vs. Top 10
CEO: Jeffrey B. Kindler
Address: 235 E. 42nd St.
New York, NY 10017
Phone: 212-573-2323
Website: www.pfizer.com
Slowing R&D has caused Pfizer's pipeline to run dry. It also lost patents on some of its best-selling drugs, including the blood pressure med Norvasc and the antidepressant Zoloft, and now faces competition from new generic versions.

The pharma's anti-smoking drug Chantix, which some users claim induces suicidal thoughts and depression, caused a public relations headache. For the year, revenue fell 7.6%. The sale of its OTC division to Johnson & Johnson in 2006 caused 2007 earnings to drop 58%, despite a boost from high-priced medications in international markets.

Revenues 48,418.0 -7.6
Profits 8,144.0 -57.9
Assets 115,268.0
Stockholders' equity 65,010.0
Market value (3/28/2008) 138,655.2
Revenues 16.8
Assets 7.1
Stockholders' equity 12.5
2007 $ 1.17
% change from 2006 -56.0
1997-2007 annual growth rate % 7.5
2007 -8.1
1997-2007 annual rate 1.2
Industry: Pharmaceuticals
1 Johnson & Johnson 35 61,095.0
2 Pfizer 47 48,418.0
3 Abbott Laboratories 96 25,914.2
4 Merck 101 24,197.7
5 Wyeth 113 22,399.8
6 Bristol-Myers Squibb 125 19,977.0
7 Eli Lilly 133 18,633.5
8 Amgen 173 14,771.0
9 Schering-Plough 212 12,690.0
10 Gilead Sciences 536 4,230.0
11 Allergan 554 3,958.9
12 Genzyme 572 3,813.5
13 Forest Laboratories 605 3,441.8
14 Hospira 608 3,436.2
15 Biogen Idec 648 3,171.6
16 Mylan 736 2,666.0
17 Barr Pharmaceuticals 760 2,557.6
18 Watson Pharmaceuticals 775 2,496.7
19 King Pharmaceuticals 857 2,136.5
20 NBTY 894 2,014.5
21 Cephalon 952 1,772.6
From the May 5, 2008 issue
See Pfizer in...
...Featured Companies
...Top 50 Headquarters
MAPS
...What Readers Say
They speak out on Pfizer and other 500 companies...
 
 
 
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.